SecBot SecBot
8-K ·Filed Mar 12, 2026

TOVX

Theriva Biologics, Inc.
MIXED
Impact 6/10
Horizonmonths Processed8mo ago SEC0001104659-26-026765
8-K Item 2.02: Earnings release
Actionable Insight ◆ Mixed

Monitor upcoming FDA End-of-Phase 2 meeting for VCN-01 in pancreatic cancer and track achievement of milestones from the SYN-020 licensing deal. The going concern qualification warrants attention to future financing needs despite current cash runway into Q1 2027.

DirectionMixed
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$0.1800
T+0 close · Mar 12, 2026 · via day close
Latest settled
+44.44%
T+60 · $0.2600
Vs SPY
+33.75%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 12 $0.1800entry
  2. T+1 · 8mo ago 0.00%α +0.60% · $0.1800
  3. T+5 · 8mo ago +5.56%α +6.53% · $0.1900
  4. T+20 · 7mo ago +27.78%α +25.80% · $0.2300
  5. T+60 · 5mo ago +44.44%α +33.75% · $0.2600
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Theriva Biologics reported financial results for 2025 and provided corporate updates, including licensing SYN-020 to Rasayana Therapeutics for up to $38 million in potential milestones, advancing VCN-01 toward pivotal trials in pancreatic cancer and retinoblastoma, and maintaining a cash runway into Q1 2027. The company incurred a net loss of $23.7 million in 2025, driven by a $9 million contingent consideration adjustment.

Key Financial Metrics

EPS
$-2.08

Key Facts

  • Licensed SYN-020 to Rasayana Therapeutics for up to $38 million in potential milestones plus royalties
  • Received $300,000 upfront payment from Rasayana with potential for $16M in development milestones and $22M in sales milestones
  • Cash and cash equivalents were $13.1 million as of December 31, 2025, with $15.2 million as of February 26, 2026
  • Net loss of $23.7 million for 2025, compared to $25.7 million in 2024
  • General and administrative expenses increased 109% to $15.4 million due to a $9 million contingent consideration adjustment
  • Research and development expenses decreased 28% to $8.6 million
  • Received positive scientific advice from EMA on Phase 3 trial design for VCN-01 in pancreatic cancer
  • Audited financial statements include a going concern qualification

Financial Impact

Net loss of $23.7 million in 2025 with $9 million contingent consideration adjustment; $300,000 upfront payment from SYN-020 licensing with potential for up to $38 million in total milestones

net lossgeneral and administrative expensescash positiongoing concern

Risk Factors

  • Going concern qualification in audited financial statements indicates substantial doubt about the company's ability to continue operations
  • High dependence on successful development of VCN-01, which is still in clinical trials
  • Future capital requirements may necessitate additional funding rounds

Market Snapshot

Exchange
NYSE

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-026765
Document: tm268491d1_8k.htm0001104659-26-026765
Document: 0001104659-26-026765-index-headers.html0001104659-26-026765
Document: 0001104659-26-026765-index.html0001104659-26-026765
Document: 0001104659-26-026765.txt0001104659-26-026765

Track record

11 reports on TOVX

Performance horizon

3 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +17.39% at T+60 after the Aug 4, 2026 report. 3 of 5 went positive at some point.

Filters
  1. Nov 12, 20264d ago Press Release Neutral 4/10 Entry $0.1600 to $0.1441 Now $0.1400 −12.50% ▼ −9.94% −9.57% vs SPY
  2. Nov 2, 202614d ago 8-K Neutral 5/10 Entry $0.1820 to $0.1900 Now $0.1400 −23.08% ▲ +4.40% +2.74% vs SPY
  3. Oct 20, 202627d ago DEF 14A Bearish 5/10 Entry $0.1966 to $0.1900 Now $0.1400 +28.79% ▲ +3.36% +2.18% vs SPY
  4. Aug 11, 202613w ago 8-K Neutral 4/10 No price data
  5. Aug 11, 202613w ago Press Release Neutral 5/10 Entry $0.2300 to $0.2400 Now $0.1400 −39.13% ▲ +4.35% +4.10% vs SPY
  6. Aug 4, 202614w ago 8-K Bearish 4/10 Entry $0.2300 to $0.2251 Now $0.1400 +39.13% ▲ +2.13% +1.93% vs SPY
  7. Jul 7, 202618w ago 8-K Bullish 5/10 Entry $0.2354 to $0.2378 Now $0.1400 −40.53% ▲ +1.02% +1.33% vs SPY
  8. Jun 11, 202622w ago Press Release Bullish 7/10 Entry $0.3070 to $0.3038 Now $0.1400 −54.40% ▼ −1.04% −1.58% vs SPY
  9. Apr 17, 202630w ago 8-K Bullish 7/10 Entry $0.4100 to $0.3400 Now $0.1400 −65.85% ▼ −17.07% −16.42% vs SPY
  10. Mar 12, 202635w ago 8-K Mixed 6/10 Viewing Entry $0.1800 to $0.1800 Now $0.1400 −22.22% · 0.00% +0.60% vs SPY
Showing 10 of 11

US Market Status

Market Closed · Opens in 5h 59m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 12, 2026